Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 25:10:23743735231202733.
doi: 10.1177/23743735231202733. eCollection 2023.

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective

Affiliations

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective

Doris K Hansen et al. J Patient Exp. .

Abstract

A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted to better understand their MM disease journey, including first symptoms, diagnosis, ASCT, and recovery. Sixteen participants, including 12 patients with MM and 4 caregivers of patients with MM, were interviewed in focus group meetings. Pain, weakness, and bone pain were common first symptoms among patients. The MM diagnosis was often made by a hematologist or oncologist. Patients were referred to a specialized oncologist after diagnosis, who was the primary driver in making ASCT treatment decisions. Eight patients received their ASCT in the inpatient setting, with some having lengthy hospital stays; 4 received their ASCT in an outpatient setting with 3 eventually being hospitalized. The focus groups identified that patients and caregivers perceived various unmet needs and impacts on quality of life throughout their transplant journey. Educational resources and innovative therapies are needed to reduce the disease burden of MM and enhance the quality of life for both patients and their caregivers.

Keywords: autologous stem cell transplant; disease journey; focus group; multiple myeloma; patient experience.

PubMed Disclaimer

Conflict of interest statement

DKH has consulted with BMS, Karyopharm, Janssen, and Pfizer; received research funding from BMS, the International Myeloma Society, Karyopharm, and the Pentecost Family Myeloma Research Center; received honoraria from OncLive and Survivorship; and served on BMS IMW Ide-celacademic advisory board, BMS MM ASH Steering Committee, and MM Pfizer Advisory Board. TB, KF, LS, KB, Y-HL, and SH are employees of Janssen Scientific Affairs, LLC, and hold Johnson & Johnson stock. CB works for CorEvitas, which provided analytical services funded by Janssen Pharmaceuticals.

Figures

Figure 1.
Figure 1.
First symptoms of patients.
Figure 2.
Figure 2.
Patient autologous stem cell transplant recovery experience.

Similar articles

Cited by

References

    1. American Cancer Society. Key statistics about multiple myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed January 25, 2023.
    1. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94. - PMC - PubMed
    1. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327:464‐77. - PubMed
    1. Bazarbachi AH, Hamed RA, Malard F, Bazarbachi A, Harousseau J-L, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022;12:47. - PMC - PubMed
    1. Paquin AR, Kumar SK, Buadi FK, et al. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018;8:125. - PMC - PubMed

LinkOut - more resources